MTOR and neoplasm: To test whether the residual ‘resistant’ regions were PI3K–mTOR–AKT pathway dependent, the segmentation was re-run using a larger dataset that included additional tumours treated with AZD8186 and the combination of both AZD2014 and AZD8186.